Emerging Insights into Adenomyosis: Diagnosis, Treatment, and Future Directions

Emerging developments in the understanding, diagnosis, and treatment of adenomyosis show potential to improve clinical outcomes and fertility preservation for affected patients. The condition, characterized by endometrial glands within the uterine myometrium, is linked to inflammatory and endocrine changes, including increased estrogen receptor activity and progesterone resistance.

While historically associated with patients over 40, advanced imaging techniques now indicate that a notable number of younger patients are also affected.

The reported prevalence of adenomyosis ranges from 9% to 62%, with diagnostic limitations impacting data accuracy.

Diagnostic Challenges and Advances

Diagnostic ambiguities present a challenge in adenomyosis research and treatment. Diagnosis has traditionally been made through pathological examination following a hysterectomy. However, this method misses opportunities for early intervention that could enhance fertility outcomes.

Symptoms of adenomyosis are often nonspecific and vary among individuals; approximately one in three patients is asymptomatic. Common symptoms include heavy menstrual bleeding (menorrhagia), pelvic pain, fertility issues, painful menstruation (dysmenorrhea), and abnormal uterine bleeding. Clinicians are advised to consider adenomyosis in patients experiencing erratic vaginal bleeding not attributed to conditions such as polycystic ovary syndrome (PCOS) or metabolic syndrome, especially if the bleeding does not respond to hormonal contraceptive medications.

Advances in imaging have introduced noninvasive diagnostic options, including transvaginal ultrasound (TVUS) and magnetic resonance imaging (MRI) of the pelvis. A 2025 review of 12 studies reported that TVUS demonstrated an average sensitivity of 78.5% and specificity of 70.7%, while MRI showed a sensitivity of 64.8% and specificity of 87.5%.

A normal pelvic ultrasound does not exclude adenomyosis; radiologists frequently use MRI junctional zone thickness for diagnosis. Research indicates age-related differences in presentation: younger patients often exhibit severe dysmenorrhea and focal adenomyosis, while older patients more frequently present with menorrhagia, an altered junctional zone, and more severe, diffuse adenomyosis.

Evolving Treatment Approaches

Fertility-sparing treatment for adenomyosis primarily involves menstrual suppression through hormonal contraceptive medications, such as the levonorgestrel intrauterine device. Gonadotropin-releasing hormone (GnRH) antagonists may be used for cases of refractory or persistent bleeding. These hormonal therapies function by reducing estrogen concentrations, which can decrease the size of adenomyotic lesions and alleviate associated symptoms like pain and bleeding.

For patients who have completed childbearing, hysterectomy is considered the definitive treatment for adenomyosis.

Conservative uterine-sparing surgical techniques are available for patients of childbearing age to potentially preserve fertility. Excisional techniques, such as adenomyomectomy with modern reconstruction, have demonstrated pregnancy rates of approximately 50% and live birth rates of 70% in patients with focal disease. Success rates were observed to be lower in cases of diffuse disease. A 2025 review identified lesion type, location, and junctional zone thickness as predictors of fertility in adenomyosis patients undergoing conservative surgical treatment.

Emerging procedural technologies are also being explored for fertility-sparing options. High-intensity focused ultrasound (HIFU) is one such technology. A 2025 retrospective study found that adenomyosis patients who underwent HIFU had an overall pregnancy rate of 48.9%, with 51.1% of those previously experiencing infertility conceiving after the procedure. Other ablative devices, including percutaneous microwave ablation and radiofrequency ablation, are also under investigation.

A challenge in treatment involves patient reluctance to re-attempt hormonal agents due to prior negative experiences, such as mood changes or irregular bleeding. However, different generations of progestins and varied administration methods exist, suggesting that trialing different progestin therapies can be beneficial.

Remaining Gaps and Future Research

Further investigation is needed to improve adenomyosis diagnosis and treatment outcomes. Key areas include:

• Developing better tools for diagnosing and staging adenomyosis in younger women to facilitate research into fertility-enhancing and symptom-improving treatments.
• Identifying novel, non-hormonal therapies.
• Conducting research into non-contraceptive applications of hormonal agents.
• Designing studies that consider primary endpoints beyond just time to pregnancy, such as specifically targeting pain and bleeding.
• Further research into the pathogenesis of adenomyosis.
• Applying newer translational science methods to the field.